Immunotherapy – drug therapy that stimulates the immune system to attack tumors – has a good effect on some types of cancer, but its effect on lung cancer is mixed. A new study helps to clarify why the immune system responds so weakly to lung cancer, even after treatment with immunotherapy drugs. In this study on mice, researchers from the Massachusetts Institute of Technology found that bacteria found naturally…
Day: March 2, 2023
ROR2 may be a potential biomarker of prostate cancer
Prostate cancer (PCa) is the main cause of cancer-related deaths in men. Androgen deprivation therapy (ADT) is still the standard systemic treatment, but patients always progress to metastatic castrated tolerant prostate cancer (mCRP C). Most of these tumors will react to the further treatment of androgen signaling inhibitors (ASIs), but inevitably will produce drug resistance. Changes in androgen receptor (AR) and interaction pathway contribute to the sustained activity of…
AMPK activation is a promising strategy to reduce the risk of melanoma
Skin cancer is the most common cancer in the United States, with about 5 million cases every year. Melanoma is less common than other types of skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but it causes most of the death of skin cancer. The risk of melanoma is related to environmental factors, such as ultraviolet radiation (UVR) and genetic background. It is noteworthy that…
Autoimmunity in Down’s syndrome via cytokines
In a new study, researchers from the Icahn Medical College in Mount Sinai, the United States, determined which parts of the immune system of patients with Down’s syndrome had problems, which led to autoimmune diseases. Relevant research results were published online in the journal Nature. This new study complements the findings of these authors published in the journal of Immunity in October 2022, that is, the frequency of viral…